The Antidepressant Effects of an mGlu2/3 Receptor Antagonist and Ketamine Require AMPA Receptor Stimulation in the mPFC and Subsequent Activation of the 5-HT Neurons in the DRN

Neuropsychopharmacology

Volumn 41, Issue 4, 2016, Pages 1046-1056

  Fukumoto, Kenichi ^a   Iijima, Michihiko ^a   Chaki, Shigeyuki ^a  

^a Pharmacology I   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; FENCLONINE; KETAMINE; METABOTROPIC RECEPTOR ANTAGONIST; SEROTONIN; 2,3-DIOXO-6-NITRO-7-SULFAMOYLBENZO(F)QUINOXALINE; AMINO ACID; ANTIDEPRESSANT AGENT; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; QUINOXALINE DERIVATIVE; XANTHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; FORCED SWIM TEST; MALE; MEDIAL PREFRONTAL CORTEX; MOUSE; NERVE PROJECTION; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SEROTONINERGIC NERVE CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DEPRESSION; DRUG EFFECTS; NERVE TRACT; PHYSIOLOGY; PREFRONTAL CORTEX;

AMINO ACIDS; ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DORSAL RAPHE NUCLEUS; FENCLONINE; KETAMINE; MALE; MICE; MICE, INBRED C57BL; NEURAL PATHWAYS; PREFRONTAL CORTEX; QUINOXALINES; RECEPTORS, AMPA; RECEPTORS, METABOTROPIC GLUTAMATE; SEROTONERGIC NEURONS; XANTHENES;

EID: 84957846631     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.233     Document Type: Article

References (40)

1. Ago Y, Yano K, Araki R, Hiramatsu N, Kita Y, Kawasaki T et al (2013). Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice. Neuropharmacology 65: 29-38.
2. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF et al (2011). NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475: 91-95.
3. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS (2000). Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47: 351-354.
4. Chaki S, Yoshikawa R, Hirota S, Shimazaki T, Maeda M, Kawashima N et al (2004). MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant like activity. Neuropharmacology 46: 457-467.
5. Challis C, Beck SG, Berton O (2014). Optogenetic modulation of descending prefrontocortical inputs to the dorsal raphe bidirectionally bias socioaffective choices after social defeat. Front Behav Neurosci 8: 43.
6. Dwyer JM, Lepack AE, Duman RS (2012). mTOR activation is required for the antidepressant effects of mGluR2/3 blockade. Int J Neuropsychopharmacol 15: 429-434.
7. Dwyer JM, Lepack AE, Duman RS (2013). mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure. J Mol Psychiatry 1: 15.
8. Fukumoto K, Iijima M, Chaki S (2014). Serotonin-1A receptor stimulation mediates effects of a metabotropic glutamate 2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and an N-methyl-D-aspartate receptor antagonist, ketamine, in the novelty-suppressed feeding test. Psychopharmacology (Berl) 2231: 2291-2298.
9. Gigliucci V, O'Dowd G, Casey S, Egan D, Gibney S, Harkin A (2013). Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism. Psychopharmacology (Berl) 228: 157-166.
10. Gradient RA, Wedel PC, Frisbie VM, Leuchter AF, Targum SD, Truong CT et al (2012). Safety, pharmacokinetic and pharmacodynamics profile of BCI-632, a selective metabotropic glutamate 2/3 receptor antagonist, in healthy human subjects. Abstr Neurosci Meeting 42: 20.
11. Hamani C, Diwan M, Macedo CE, Brandão ML, Shumake J, Gonzalez-Lima F et al (2010). Antidepressant-like effects of medial prefrontal cortex deep brain stimulation in rats. Biol Psychiatry 67: 117-124.
12. Hascup ER, Hascup KN, Stephens M, Pomerleau F, Huettl P, Gratton A et al (2010). Rapid microelectrode measurements and the origin and regulation of extracellular glutamate in rat prefrontal cortex. J Neurochem 115: 1608-1620.
13. Ibrahim L, Diazgranados N, Luckenbaugh DA, Machado-Vieira R, Baumann J, Mallinger AG et al (2011). Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry 35: 1155-1159.
14. Iijima M, Koike H, Chaki S (2013). Effect of an mGlu2/3 receptor antagonist on depressive behavior induced by withdrawal from chronic treatment with methamphetamine. Behav Brain Res 246: 24-28.
15. Jankowski MP, Sesack SR (2004). Prefrontal cortical projections to the rat dorsal raphe nucleus: ultrastructural features and associations with serotonin and gamma-aminobutyric acid neurons. J Comp Neurol 468: 518-529.
16. Karasawa J, Shimazaki T, Kawashima N, Chaki S (2005). AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res 1042: 92-98.
17. Kawashima N, Karasawa J, Shimazaki T, Chaki S, Okuyama S, Yasuhara A et al (2005). Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors. Neurosci Lett 378: 131-134.
18. Koike H, Iijima M, Chaki S (2011a). Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists. Neuropharmacology 61: 1419-1423.
19. Koike H, Iijima M, Chaki S (2011b). Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 224: 107-111.
20. Koike H, Iijima M, Chaki S (2013a). Effects of ketamine and LY341495 on the depressive-like behavior of repeated corticosterone-injected rats. Pharmacol Biochem Behav 107: 20-23.
21. Koike H, Fukumoto K, Iijima M, Chaki S (2013b). Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression. Behav Brain Res 238: 48-52.
22. Krystal JH, Sanacora G, Duman RS (2013). Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 73: 1133-1141.
23. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M et al (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329: 959-964.
24. López-Gil X, Babot Z, Amargós-Bosch M, Suñol C, Artigas F, Adell A (2007). Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology 32: 2087-2097.
25. López-Gil X, Jiménez-Sánchez L, Romón T, Campa L, Artigas F, Adell A (2012). Importance of inter-hemispheric prefrontal connection in the effects of non-competitive NMDA receptor antagonists. Int J Neuropsychopharmacol 15: 945-956.
26. Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G (2008). Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63: 349-352.
27. Martín-Ruiz R, Puig MV, Celada P, Shapiro DA, Roth BL, Mengod G et al (2001). Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurosci 21: 9856-9866.
28. Moghaddam B, Adams B, Verma A, Daly D (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17: 2921-2927.
29. Nishitani N, Nagayasu K, Asaoka N, Yamashiro M, Shirakawa H, Nakagawa T et al (2014). Raphe AMPA receptors and nicotinic acetylcholine receptors mediate ketamine-induced serotonin release in the rat prefrontal cortex. Int J Neuropsychopharmacol 17: 1321-1326.
30. Nowak K, Meyza K, Nikolaev E, Hunt MJ, Kasicki S (2012). Local blockade of NMDA receptors in the rat prefrontal cortex increases c-Fos expression in multiple subcortical regions. Acta Neurobiol Exp (Wars) 72: 207-218.
31. Pałucha-Poniewiera A, Wierońska JM, Brański P, Stachowicz K, Chaki S, Pilc A (2010). On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039. Psychopharmacology (Berl) 212: 523-535.
32. Paxinos G, Franklin K (1997). The mouse brain in stereotaxic coordinates. Academic, San Diego.
33. Pollak Dorocic I, Fürth D, Xuan Y, Johansson Y, Pozzi L, Silberberg G et al (2014). A whole-brain atlas of inputs to serotonergic neurons of the dorsal and median raphe nuclei. Neuron 83: 663-678.
34. Sugimoto Y, Yamamoto M, Tagawa N, Kobayashi Y, Mitsui-Saitoh K, Hotta Y et al (2011). Differences between mice strains in response to paroxetine in the forced swimming test: involvement of serotonergic or noradrenergic systems. Eur J Pharmacol 672: 121-125.
35. Varga V, Kocsis B, Sharp T (2003). Electrophysiological evidence for convergence of inputs from the medial prefrontal cortex and lateral habenula on single neurons in the dorsal raphe nucleus. Eur J Neurosci 17: 280-286.
36. Wang QP, Ochiai H, Nakai Y (1992). GABAergic innervation of serotonergic neurons in the dorsal raphe nucleus of the rat studied by electron microscopy double immunostaining. Brain Res Bull 29: 943-948.
37. Warden MR, Selimbeyoglu A, Mirzabekov JJ, Lo M, Thompson KR, Kim SY et al (2012). A prefrontal cortex-brainstem neuronal projection that controls response to behavioural challenge. Nature 492: 428-432.
38. Weissbourd B, Ren J, DeLoach KE, Guenthner CJ, Miyamichi K, Luo L (2014). Presynaptic partners of dorsal raphe serotonergic and GABAergic neurons. Neuron 83: 645-662.
39. Yamanaka H, Yokoyama C, Mizuma H, Kurai S, Finnema SJ, Halldin C et al (2014). A possible mechanism of the nucleus accumbens and ventral pallidum 5-HT1B receptors underlying the antidepressant action of ketamine: a PET study with macaques. Transl Psychiatry 4: e342.
40. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA (2006). A randomized trial of an N-methyl-Daspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856-864.